Atul Pande - Net Worth and Insider Trading
Atul Pande Net Worth
The estimated net worth of Atul Pande is at least $3 Million dollars as of 2024-11-13. Atul Pande is the Director of Immunovant Inc and owns about 103,158 shares of Immunovant Inc (IMVT) stock worth over $3 Million. Atul Pande is the Director of Sio Gene Therapies Inc and owns about 33,370 shares of Sio Gene Therapies Inc (SIOX) stock worth over $15,951. Atul Pande is also the Director of Karuna Therapeutics Inc and owns about 0 shares of Karuna Therapeutics Inc (KRTX) stock worth over $0. Details can be seen in Atul Pande's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atul Pande has not made any transactions after 2023-12-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Atul Pande
Atul Pande Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Atul Pande owns 4 companies in total, including Karuna Therapeutics Inc (KRTX) , Sio Gene Therapies Inc (SIOX) , and Immunovant Inc (IMVTU) among others .
Click here to see the complete history of Atul Pande’s form 4 insider trades.
Insider Ownership Summary of Atul Pande
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | 2022-02-01 | director |
| SIOX | Sio Gene Therapies Inc | 2020-11-24 | director |
| IMVTU | Immunovant Inc | 2020-05-15 | director |
 | | 2023-12-01 | director |
Atul Pande Latest Holdings Summary
Atul Pande currently owns a total of 3 stocks. Among these stocks, Atul Pande owns 103,158 shares of Immunovant Inc (IMVT) as of December 1, 2023, with a value of $3 Million and a weighting of 99.47%. Atul Pande owns 33,370 shares of Sio Gene Therapies Inc (SIOX) as of November 24, 2020, with a value of $15,951 and a weighting of 0.53%. Atul Pande also owns 0 shares of Karuna Therapeutics Inc (KRTX) as of February 1, 2022, with a value of $0 and a weighting of 0%.
Latest Holdings of Atul Pande
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IMVT | Immunovant Inc | 2023-12-01 | 103,158 | 29.27 | 3,019,435 |
| SIOX | Sio Gene Therapies Inc | 2020-11-24 | 33,370 | 0.48 | 15,951 |
| KRTX | Karuna Therapeutics Inc | 2022-02-01 | 0 | 329.83 | 0 |
Holding Weightings of Atul Pande
Atul Pande Form 4 Trading Tracker
According to the SEC Form 4 filings, Atul Pande has made a total of 2 transactions in Immunovant Inc (IMVT) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Immunovant Inc is the sale of 12,350 shares on December 1, 2023, which brought Atul Pande around $490,666.
According to the SEC Form 4 filings, Atul Pande has made a total of 3 transactions in Sio Gene Therapies Inc (SIOX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Sio Gene Therapies Inc is the acquisition of 10,000 shares on November 24, 2020, which cost Atul Pande around $23,400.
According to the SEC Form 4 filings, Atul Pande has made a total of 19 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 0 buys and 19 sells. The most-recent trade in Karuna Therapeutics Inc is the sale of 2,500 shares on February 1, 2022, which brought Atul Pande around $277,000.
Insider Trading History of Atul Pande
- 1
Atul Pande Trading Performance
GuruFocus tracks the stock performance after each of Atul Pande's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atul Pande is 42.32%. GuruFocus also compares Atul Pande's trading performance to market benchmark return within the same time period. The performance of stocks bought by Atul Pande within 3 months outperforms 5 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Atul Pande's insider trading performs compared to the benchmark.
Performance of Atul Pande
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 37.52 | | | | | |
| Relative Return to S&P 500(%) | 31.65 | | | | | |
Atul Pande Ownership Network
Ownership Network List of Atul Pande
Ownership Network Relation of Atul Pande
Atul Pande Owned Company Details
What does Karuna Therapeutics Inc do?
Who are the key executives at Karuna Therapeutics Inc?
Atul Pande is the director of Karuna Therapeutics Inc. Other key executives at Karuna Therapeutics Inc include Chief Medical Officer Stephen K. Brannan , Chief Financial Officer Jason Parker Brown , and Chief Financial Officer Troy A. Ignelzi .
Karuna Therapeutics Inc (KRTX) Insider Trades Summary
Over the past 18 months, Atul Pande made no insider transaction in Karuna Therapeutics Inc (KRTX). Other recent insider transactions involving Karuna Therapeutics Inc (KRTX) include a net sale of 55,000 shares made by Stephen K. Brannan , a net sale of 41,429 shares made by Jeffrey M Jonas , and a net sale of 10,500 shares made by Troy A. Ignelzi .
In summary, during the past 3 months, insiders sold 0 shares of Karuna Therapeutics Inc (KRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 106,929 shares of Karuna Therapeutics Inc (KRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 106,929 shares.
Karuna Therapeutics Inc (KRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Karuna Therapeutics Inc Insider Transactions
Atul Pande Mailing Address
Above is the net worth, insider trading, and ownership report for Atul Pande. You might contact Atul Pande via mailing address: C/o Axovant Sciences, Inc., 1441 Broadway, 3rd Floor, New York Ny 10018.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
